CO6180432A2 - Anticuerpos agonistas del trkb y usos de los mismos - Google Patents
Anticuerpos agonistas del trkb y usos de los mismosInfo
- Publication number
- CO6180432A2 CO6180432A2 CO09047482A CO09047482A CO6180432A2 CO 6180432 A2 CO6180432 A2 CO 6180432A2 CO 09047482 A CO09047482 A CO 09047482A CO 09047482 A CO09047482 A CO 09047482A CO 6180432 A2 CO6180432 A2 CO 6180432A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- seq
- variable region
- chain variable
- trkb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un anticuerpo agonista aislado del Receptor B Tirosinquinasa (TrkB). 2.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo es un anticuerpo humanizado. 3.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo es un anticuerpo de cadena sencilla. 4.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo no se une al Receptor A Tirosinquinasa o al Receptor C Tirosinquinasa. 5.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo se une al Dominio de Unión de Ligandos (LBD, por su sigla en inglés) del TrkB. 6.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo compite con la unión del Factor Neurotrófico Derivado del Cerebro (BDNF) al TrkB. 7.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo comprende i. una región variable de cadena pesada que comprende la SEQ ID No. 7; y ii. una región variable de cadena liviana que comprende la SEQ ID No. 8.8.- El anticuerpo de la Reivindicación 7, en donde el anticuerpo comprende i. una región variable de cadena pesada que comprende la SEQ ID No. 7, SEQ ID No: 11, y SEQ ID No: 15; y ii. una región variable de cadena liviana que comprende la SEQ ID No. 8, SEQ ID No: 12, y SEQ ID No: 16. 9.- El anticuerpo de la Reivindicación 8, en donde el anticuerpo comprende i. una región variable de cadena pesada que comprende la SEQ ID No. 3; y ii. una región variable de cadena liviana que comprende la SEQ ID No. 4. 10.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo no se une al LBD del TrkB. 11.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo no compite con la unión del factor Neurotrófico Derivado del Cerebro (BDNF) al TrkB. 12.- El anticuerpo de la Reivindicación 1, en donde el anticuerpo comprende i. una región variable de cadena pesada que comprende la SEQ ID No. 5; y ii. una región variable de cadena liviana que comprende la SEQ ID No. 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85816906P | 2006-11-09 | 2006-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6180432A2 true CO6180432A2 (es) | 2010-07-19 |
Family
ID=39365312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09047482A CO6180432A2 (es) | 2006-11-09 | 2009-05-11 | Anticuerpos agonistas del trkb y usos de los mismos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20100150914A1 (es) |
| EP (1) | EP2087007A2 (es) |
| JP (1) | JP2010509354A (es) |
| KR (1) | KR20090088896A (es) |
| CN (1) | CN101573381A (es) |
| AR (1) | AR063640A1 (es) |
| AU (1) | AU2007316418A1 (es) |
| BR (1) | BRPI0719000A2 (es) |
| CA (1) | CA2669205A1 (es) |
| CL (1) | CL2007003236A1 (es) |
| CO (1) | CO6180432A2 (es) |
| CR (1) | CR10779A (es) |
| DO (1) | DOP2009000102A (es) |
| EA (1) | EA200970469A1 (es) |
| EC (1) | ECSP099392A (es) |
| IL (1) | IL198468A0 (es) |
| MA (1) | MA30922B1 (es) |
| MX (1) | MX2009004881A (es) |
| NI (1) | NI200900081U (es) |
| NO (1) | NO20092217L (es) |
| PE (1) | PE20081168A1 (es) |
| RU (1) | RU2009121641A (es) |
| SM (1) | SMAP200900040A (es) |
| TN (1) | TN2009000181A1 (es) |
| TW (1) | TW200829270A (es) |
| WO (1) | WO2008058127A2 (es) |
| ZA (1) | ZA200902943B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100089851A (ko) * | 2007-10-23 | 2010-08-12 | 노파르티스 아게 | 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도 |
| MX2010007841A (es) * | 2008-01-17 | 2010-09-28 | Irm Llc | Anticuerpos anti-trkb mejorados. |
| US8748493B2 (en) * | 2009-03-20 | 2014-06-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders |
| GB2491106A (en) * | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
| CN104244981A (zh) * | 2011-12-09 | 2014-12-24 | 诺和诺德A/S | Glp-1激动剂 |
| CN102901815B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法 |
| CN102944674B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法 |
| JP6868394B2 (ja) | 2014-05-16 | 2021-05-12 | ファイザー・インク | 二重特異性抗体 |
| CN104524568B (zh) * | 2015-01-08 | 2018-04-20 | 中国人民解放军第二军医大学 | 一种治疗肥胖症的药物组合物及其应用 |
| EP3328898B8 (en) | 2015-07-28 | 2024-04-10 | 6452728 Canada Corp. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| US11078287B2 (en) | 2015-11-17 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| SG11201909708VA (en) * | 2017-04-21 | 2019-11-28 | Mellitus Llc | Methods and antibodies for diabetes-related applications |
| US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| SG11202002665UA (en) | 2017-11-30 | 2020-04-29 | Regeneron Pharma | Anti-trkb monoclonal antibodies and methods of use |
| JP7411559B2 (ja) | 2018-02-26 | 2024-01-11 | ミネルバ バイオテクノロジーズ コーポレーション | Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法 |
| CN110818797B (zh) * | 2018-08-09 | 2022-11-04 | 东莞市朋志生物科技有限公司 | 一种抗人ca153蛋白的重组抗体 |
| JP2023546229A (ja) | 2020-10-21 | 2023-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患の処置のためのアゴニスト性ＴｒｋＢ結合分子 |
| WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
| US5601820A (en) * | 1994-07-07 | 1997-02-11 | Children's Hospital Of Philadelphia | Compositions and methods of making and using human full length TRK-B |
| CA2610771A1 (en) * | 2005-06-06 | 2006-12-14 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
| EP1988920A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
| CN101400367A (zh) * | 2006-02-02 | 2009-04-01 | 瑞纳神经科学公司 | 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法 |
-
2007
- 2007-11-06 WO PCT/US2007/083774 patent/WO2008058127A2/en active Application Filing
- 2007-11-06 BR BRPI0719000-0A patent/BRPI0719000A2/pt not_active IP Right Cessation
- 2007-11-06 AU AU2007316418A patent/AU2007316418A1/en not_active Abandoned
- 2007-11-06 KR KR1020097011751A patent/KR20090088896A/ko not_active Application Discontinuation
- 2007-11-06 RU RU2009121641/10A patent/RU2009121641A/ru unknown
- 2007-11-06 CA CA002669205A patent/CA2669205A1/en not_active Abandoned
- 2007-11-06 JP JP2009536439A patent/JP2010509354A/ja active Pending
- 2007-11-06 EP EP07868672A patent/EP2087007A2/en not_active Withdrawn
- 2007-11-06 US US12/516,187 patent/US20100150914A1/en not_active Abandoned
- 2007-11-06 MX MX2009004881A patent/MX2009004881A/es not_active Application Discontinuation
- 2007-11-06 CN CNA2007800442715A patent/CN101573381A/zh active Pending
- 2007-11-06 EA EA200970469A patent/EA200970469A1/ru unknown
- 2007-11-09 PE PE2007001546A patent/PE20081168A1/es not_active Application Discontinuation
- 2007-11-09 TW TW096142572A patent/TW200829270A/zh unknown
- 2007-11-09 CL CL200703236A patent/CL2007003236A1/es unknown
- 2007-11-09 AR ARP070105005A patent/AR063640A1/es unknown
-
2009
- 2009-04-29 ZA ZA200902943A patent/ZA200902943B/xx unknown
- 2009-04-30 IL IL198468A patent/IL198468A0/en unknown
- 2009-05-07 CR CR10779A patent/CR10779A/es not_active Application Discontinuation
- 2009-05-08 NI NI200900081U patent/NI200900081U/es unknown
- 2009-05-08 DO DO2009000102A patent/DOP2009000102A/es unknown
- 2009-05-08 TN TNP2009000181A patent/TN2009000181A1/fr unknown
- 2009-05-11 CO CO09047482A patent/CO6180432A2/es not_active Application Discontinuation
- 2009-05-27 MA MA31923A patent/MA30922B1/fr unknown
- 2009-05-28 SM SM200900040T patent/SMAP200900040A/it unknown
- 2009-06-08 EC EC2009009392A patent/ECSP099392A/es unknown
- 2009-06-09 NO NO20092217A patent/NO20092217L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007003236A1 (es) | 2008-06-13 |
| WO2008058127A2 (en) | 2008-05-15 |
| ZA200902943B (en) | 2010-05-26 |
| EA200970469A1 (ru) | 2010-04-30 |
| WO2008058127A9 (en) | 2008-08-21 |
| KR20090088896A (ko) | 2009-08-20 |
| US20100150914A1 (en) | 2010-06-17 |
| AR063640A1 (es) | 2009-02-04 |
| PE20081168A1 (es) | 2008-09-22 |
| NO20092217L (no) | 2009-06-09 |
| SMAP200900040A (it) | 2010-01-19 |
| CN101573381A (zh) | 2009-11-04 |
| EP2087007A2 (en) | 2009-08-12 |
| NI200900081U (es) | 2010-03-16 |
| CA2669205A1 (en) | 2008-05-15 |
| ECSP099392A (es) | 2009-07-31 |
| MA30922B1 (fr) | 2009-11-02 |
| AU2007316418A1 (en) | 2008-05-15 |
| BRPI0719000A2 (pt) | 2013-12-10 |
| TW200829270A (en) | 2008-07-16 |
| IL198468A0 (en) | 2011-08-01 |
| MX2009004881A (es) | 2009-05-21 |
| DOP2009000102A (es) | 2010-10-31 |
| RU2009121641A (ru) | 2010-12-20 |
| JP2010509354A (ja) | 2010-03-25 |
| CR10779A (es) | 2009-07-03 |
| WO2008058127A3 (en) | 2008-10-02 |
| TN2009000181A1 (en) | 2010-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6180432A2 (es) | Anticuerpos agonistas del trkb y usos de los mismos | |
| AR119754A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| PE20120414A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
| PE20221007A1 (es) | Anticuerpos anti-receptor de transferrina con afinidad disenada | |
| CR20140239A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (divisional de 2013-0351) | |
| CR11030A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos | |
| AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
| ES2722300T3 (es) | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso | |
| AR063090A1 (es) | Proteinas de union al antigeno del receptor de la il-17 | |
| ES2683847T3 (es) | Inmunoglobulina citotóxica | |
| AR070202A1 (es) | Anticuerpos anti- trkb mejorados | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PE20121129A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
| AR076564A1 (es) | Anticuerpos humanizados de axl(receptor de tirosina quinasa) | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| EA200800812A1 (ru) | Композиции антитела против cd3 | |
| EA200870411A1 (ru) | Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы | |
| RS54046B1 (en) | ANTI-MIOSTATIN ANTITELA | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| PE20091520A1 (es) | Anticuerpos bivalentes biespecificos | |
| CR10563A (es) | Anticuerpos monoclonales ant-il-6 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |